Previous 10 | Next 10 |
home / stock / sphdf / sphdf news
Ad hoc announcement pursuant to Art. 53 LR Food and Drug Administration (FDA) approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in children and adults aged 2 years and older U.S. license holder Catalyst Pharmaceuticals plans for commercial ...
2023-10-20 15:00:13 ET More on the markets S&P 500 Will Likely Underperform And 5% Money Markets Are NOT The Answer Equities Climbing A Wall Of Worry (Technical Analysis) SPY: Short-Term Bounce Testing The Downtrends (Technical Analysis) Here is why you s...
Ad hoc announcement pursuant to Art. 53 LR Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for AGAMREE® (vamorolone) for the treatment Duchenne muscular dystrophy (DMD) in children and adults aged 4 years and older European Commission (EC) decisi...
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT . Details are at the end of this news release . Revenue from contracts with customers of CHF 3.9 million (H1-2022: CHF 6.3 million)...
Ad hoc announcement pursuant to Art. 53 LR Chies i Group acquires entire idebenone business including Raxone in Leber's hereditary optic neuropathy (L HON ) Chiesi Group assumes French reimbursement liability of EUR 25.3 million from Santhera ...
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, July 19 , 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) , annou...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 29 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) ...
Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland , with a large majority . Particip...
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 1 4 : 3 0 CEST / 1 3 :30 BST / 08 :30 EDT. Details are at the end of this news release. Santhera will receive USD 90 million upfront at ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 6 , 202 3 – Santhera Pharmaceuticals (SIX: SANN) ...
News, Short Squeeze, Breakout and More Instantly...
Santhera Pharms Hldgs Ltd Company Name:
SPHDF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full R...
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD...